{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T15:59:28Z","timestamp":1783958368729,"version":"3.55.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T00:00:00Z","timestamp":1717718400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Pfizer Inc"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1136\/ard-2023-225094","type":"journal-article","created":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T17:18:45Z","timestamp":1717780725000},"page":"1561-1571","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary results of an open-label, long-term extension study"],"prefix":"10.1016","volume":"83","clinical-trial-number":[{"clinical-trial-number":"nct01500551","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01513902","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02592434","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03000439","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01500551","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01513902","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02592434","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02592434","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03000439","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9478-2987","authenticated-orcid":false,"given":"Hermine I","family":"Brunner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan D","family":"Akikusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1999-6341","authenticated-orcid":false,"given":"Eslam","family":"Al-Abadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F","family":"Bohnsack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina Lucica","family":"Boteanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaelle","family":"Chedeville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Cuttica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"De La Pena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozgur","family":"Kasapcopur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Kobusinska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5923-7051","authenticated-orcid":false,"given":"Grant S","family":"Schulert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Neiva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Rivas-Chacon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Cruz","family":"Rizo Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3823-4676","authenticated-orcid":false,"given":"Monica","family":"Vazquez-Del Mercado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Wagner-Weiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer E","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carine","family":"Wouters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Posner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Wouters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Kanik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shixue","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1604-0130","authenticated-orcid":false,"given":"Daniel J","family":"Lovell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8407-7782","authenticated-orcid":false,"given":"Nicolino","family":"Ruperto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard-2023-225094_bib1","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3899\/jrheum.180168","article-title":"Toward new classification criteria for juvenile idiopathic arthritis: frst steps, pediatric rheumatology international trials organization international consensus","volume":"46","author":"Martini","year":"2019","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2023-225094_bib2","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0140-6736(08)60998-8","article-title":"Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial","volume":"372","author":"Ruperto","year":"2008","journal-title":"Lancet"},{"key":"10.1136\/ard-2023-225094_bib3","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa0706290","article-title":"Adalimumab with or without methotrexate in juvenile rheumatoid arthritis","volume":"359","author":"Lovell","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2023-225094_bib4","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1002\/art.22838","article-title":"A randomized, placebo-controlled trial of Infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis","volume":"56","author":"Ruperto","year":"2007","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-225094_bib5","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","article-title":"Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis","volume":"367","author":"De Benedetti","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2023-225094_bib6","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","article-title":"Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis","volume":"367","author":"Ruperto","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2023-225094_bib7","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1136\/annrheumdis-2014-205351","article-title":"Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial","volume":"74","author":"Brunner","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-225094_bib8","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/annrheumdis-2016-210456","article-title":"Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial","volume":"77","author":"Brunner","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-225094_bib9","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S2352-4642(18)30034-8","article-title":"Current and future perspectives in the management of juvenile idiopathic arthritis","volume":"2","author":"Ruperto","year":"2018","journal-title":"Lancet Child Adolesc Health"},{"key":"10.1136\/ard-2023-225094_bib10","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1001\/jama.2011.1671","article-title":"Factors associated with treatment response to etanercept in juvenile idiopathic arthritis","volume":"306","author":"Otten","year":"2011","journal-title":"JAMA"},{"key":"10.1136\/ard-2023-225094_bib11","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/art.41390","article-title":"New medications are needed for children with juvenile idiopathic arthritis","volume":"72","author":"Brunner","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-225094_bib12","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S2352-4642(19)30027-6","article-title":"Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study","volume":"3","author":"Consolaro","year":"2019","journal-title":"Lancet Child Adolesc Health"},{"key":"10.1136\/ard-2023-225094_bib13","author":"US Food and Drug Administration"},{"key":"10.1136\/ard-2023-225094_bib14","author":"European Medicines Agency"},{"key":"10.1136\/ard-2023-225094_bib15","unstructured":"Clinicaltrials.Gov. A safety, efficacy and pharmacokinetics study of tofacitinib in pediatric patients with sJIA. 2023. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03000439, [Accessed 22 Apr 2024]."},{"key":"10.1136\/ard-2023-225094_bib16","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12969-017-0212-y","article-title":"Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study","volume":"15","author":"Ruperto","year":"2017","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1136\/ard-2023-225094_bib17","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1016\/S0140-6736(21)01255-1","article-title":"Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial","volume":"398","author":"Ruperto","year":"2021","journal-title":"Lancet"},{"key":"10.1136\/ard-2023-225094_bib18","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1136\/adc.2010.188946","article-title":"Networking in paediatrics: the example of the Paediatric Rheumatology International Trials Organisation (PRINTO)","volume":"96","author":"Ruperto","year":"2011","journal-title":"Arch Dis Child"},{"key":"10.1136\/ard-2023-225094_bib19","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12969-018-0261-x","article-title":"Pediatric rheumatology collaborative study group \u2013 over four decades of pivotal clinical drug research in pediatric rheumatology","volume":"16","author":"Brunner","year":"2018","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1136\/ard-2023-225094_bib20","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3414\/ME12-01-0063","article-title":"The standardization of uveitis nomenclature (SUN) project. development of a clinical evidence base utilizing Informatics tools and techniques","volume":"52","author":"Trusko","year":"2013","journal-title":"Methods Inf Med"},{"key":"10.1136\/ard-2023-225094_bib21","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1136\/annrheumdis-2015-208982","volume":"75","author":"Ravelli","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-225094_bib22","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1002\/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R","article-title":"Preliminary definition of improvement in juvenile arthritis","volume":"40","author":"Giannini","year":"1997","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-225094_bib23","first-page":"S1","article-title":"Cross-cultural adaptation and Psychometric evaluation of the childhood health assessment questionnaire (CHAQ) and the child health questionnaire (CHQ) in 32 countries. review of the general methodology","volume":"19","author":"Ruperto","year":"2001","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard-2023-225094_bib24","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1002\/1529-0131(200108)44:8<1768::AID-ART312>3.0.CO;2-Q","article-title":"The clinical meaning of functional outcome scores in children with juvenile arthritis","volume":"44","author":"Dempster","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2023-225094_bib25","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0304-3959(94)00178-H","article-title":"When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function","volume":"61","author":"Serlin","year":"1995","journal-title":"Pain"},{"key":"10.1136\/ard-2023-225094_bib26","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12969-016-0085-5","article-title":"Clinical outcome measures in juvenile idiopathic arthritis","volume":"14","author":"Consolaro","year":"2016","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1136\/ard-2023-225094_bib27","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1002\/art.34373","article-title":"Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: defining criteria based on the juvenile arthritis disease activity score","volume":"64","author":"Consolaro","year":"2012","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-225094_bib28","first-page":"1058","article-title":"Preliminary definition of disease flare in juvenile rheumatoid arthritis","volume":"29","author":"Brunner","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2023-225094_bib29","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/acr.20497","article-title":"American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis","volume":"63","author":"Wallace","year":"2011","journal-title":"Arthritis Care Res"},{"key":"10.1136\/ard-2023-225094_bib30","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1741-7015-8-18","article-title":"Statement: updated guidelines for reporting parallel group randomised trials","volume":"8","author":"Schulz","year":"2010","journal-title":"BMC Med"},{"key":"10.1136\/ard-2023-225094_bib31","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/S0140-6736(00)04337-3","article-title":"The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials","volume":"357","author":"Moher","year":"2001","journal-title":"Lancet"},{"key":"10.1136\/ard-2023-225094_bib32","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"key":"10.1136\/ard-2023-225094_bib33","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1002\/art.27431","article-title":"Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis","volume":"62","author":"Ruperto","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2023-225094_bib34","doi-asserted-by":"crossref","first-page":"4495","DOI":"10.1093\/rheumatology\/keab021","article-title":"Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis","volume":"60","author":"Ruperto","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2023-225094_bib35","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/art.41528","article-title":"Efficacy and safety of tocilizumab for polyarticular-course juvenile idiopathic arthritis in the open-label two-year extension of a phase III trial","volume":"73","author":"Brunner","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-225094_bib36","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1002\/art.34458","article-title":"Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment","volume":"64","author":"Beukelman","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2023-225094_bib37","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1002\/art.37866","article-title":"Brief report: incidence of selected opportunistic infections among children with juvenile idiopathic arthritis","volume":"65","author":"Beukelman","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2023-225094_bib38","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1002\/art.40466","article-title":"Subcutaneous abatacept in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase III open-label study","volume":"70","author":"Brunner","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-225094_bib39","doi-asserted-by":"crossref","first-page":"e001395","DOI":"10.1136\/rmdopen-2020-001395","article-title":"Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme","volume":"6","author":"Cohen","year":"2020","journal-title":"RMD Open"},{"key":"10.1136\/ard-2023-225094_bib40","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s40264-020-00904-9","article-title":"An integrated analysis of the safety of tofacitinib in psoriatic arthritis across phase III and long-term extension studies with comparison to real-world observational data","volume":"43","author":"Burmester","year":"2020","journal-title":"Drug Saf"},{"key":"10.1136\/ard-2023-225094_bib41","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X20936059","article-title":"JAK inhibitors and infections risk: focus on herpes Zoster","volume":"12","author":"Sunzini","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1136\/ard-2023-225094_bib42","doi-asserted-by":"crossref","first-page":"S353","DOI":"10.14309\/01.ajg.0000704860.70861.89","article-title":"Tofacitinib for the treatment of ulcerative colitis: up to 6.8 years of safety data from global clinical trials [abstract]","volume":"115","author":"Sandborn","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1136\/ard-2023-225094_bib43","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2023-225094_bib44","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1136\/ard-2022-223715","article-title":"Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL surveillance","volume":"82","author":"Kristensen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-225094_bib45","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1136\/ard-2022-222259","article-title":"Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL surveillance","volume":"82","author":"Charles-Schoeman","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-225094_bib46","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1136\/annrheumdis-2018-213030","article-title":"Treating juvenile idiopathic arthritis to target: recommendations of an international task force","volume":"77","author":"Ravelli","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-225094_bib47","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.3899\/jrheum.181088","article-title":"Establishing an updated core domain set for studies in juvenile idiopathic arthritis: a report from the OMERACT 2018 JIA workshop","volume":"46","author":"Morgan","year":"2019","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2023-225094_bib48","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/acr.24384","article-title":"Functional ability and health-related quality of life in randomized controlled trials of tocilizumab in patients with juvenile idiopathic arthritis","volume":"73","author":"Brunner","year":"2021","journal-title":"Arthritis Care Res"},{"key":"10.1136\/ard-2023-225094_bib49","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1002\/acr.20283","article-title":"Abatacept improves health-related quality of life, pain, sleep quality, and daily participation in subjects with juvenile idiopathic arthritis","volume":"62","author":"Ruperto","year":"2010","journal-title":"Arthritis Care Res"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724665489?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724665489?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard-2023-225094","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T08:51:51Z","timestamp":1739523111000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724665489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":49,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0003496724665489"],"URL":"https:\/\/doi.org\/10.1136\/ard-2023-225094","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary results of an open-label, long-term extension study","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard-2023-225094","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2024 \u00a9 Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by Elsevier Inc on behalf of EULAR. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}